← Eichor
Study identifier: NCT03382158 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

International PPB/DICER1 Registry

Condition: Pleuropulmonary Blastoma · Sertoli-Leydig Cell Tumor · DICER1 Syndrome  ·  Sponsor: Children's Hospitals and Clinics of Minnesota

PhaseN/A
Planned participants3400
Who can joinAll sexes, 0 Minutes to 100 Years
Healthy volunteersYes

About this study

Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Kris Ann P Schultz, MD  ·  612-813-7121  ·  krisann.schultz@childrensmn.org

Paige HR Mallinger, MS  ·  612-813-7115  ·  paige.mallinger@childrensmn.org

Always discuss trial participation with your own doctor first.

Locations (1)

Children's MinnesotaMinneapolis, Minnesota, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03382158